Results 91 to 100 of about 10,444 (254)

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Complex Regional Pain Syndrome

Brain and Behavior
Background Complex regional pain syndrome is characterized by severe, persistent pain. Emerging evidence suggests that cannabis‐based medicinal products may represent a new therapeutic option.
Lilia Evans, Simon Erridge, Madhur Varadpande, Arushika Aggarwal, Isaac Cowley, Evonne Clarke, Katy McLachlan, Ross Coomber, James J. Rucker, Michael Platt, Mikael H. Sodergren   +10 more
doaj   +1 more source

Prevalence of novel psychoactive substances in selected clinical urine specimens submitted for drug monitoring

Journal of Forensic Sciences, EarlyView.
Abstract Novel psychoactive substances (NPS) are compounds emerging as alternatives to more established drugs of abuse. They are constantly changing and being modified, which makes their detection difficult. The study objective was to determine the prevalence of NPS in selected clinical specimens. Deidentified urine specimen remnants were analyzed that
Jillian R. Neifeld, Theresa M. Meli, Sarah H. Bartock   +2 more
wiley   +1 more source

Exploring the Materiality of Data Breach Disclosures on the Australian Stock Exchange

Abacus, EarlyView.
This study examines Australian Stock Exchange (ASX) data breach announcements to provide insights into the extent and nature of data breach disclosures, as well as the costs, particularly to stakeholder relationships. Using a dataset of all data breach‐related announcements on the ASX, we identify a lack of data breach disclosure and, where disclosures
Jane Andrew, Max Baker, Xiaojiao Wang, Monique Sheehan   +3 more
wiley   +1 more source

Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark, Mussie Msghina, Axel Nordenskjöld   +2 more
wiley   +1 more source

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source

Medicinal Cannabis and the Intestinal Microbiome

Pharmaceuticals
Historically, the multiple uses of cannabis as a medicine, food, and for recreational purposes as a psychoactive drug span several centuries. The various components of the plant (i.e., seeds, roots, leaves and flowers) have been utilized to alleviate symptoms of inflammation and pain (e.g., osteoarthritis, rheumatoid arthritis), mood disorders such as ...
Luis Vitetta, Tamara Nation, Debbie Oldfield, Michael Thomsen   +3 more
openaire   +3 more sources

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Envisaging challenges for the emerging medicinal Cannabis sector in Lesotho

Journal of Cannabis Research
Background Cultivation of Cannabis and its use for medical purposes has existed for millennia on the African continent. The plant has also been widely consumed in the African continent since time immemorial.
Regina M. Thetsane
doaj   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source